Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.64 |
| ▸ | APP | P05067 | 2/20 | 0.50 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.45 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.45 |
| ▸ | IKBKB | O14920 | 3/20 | 0.44 |
| ▸ | CHUK | O15111 | 1/20 | 0.44 |
| ▸ | IKBKG | Q9Y6K9 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | NQO1 | P15559 | 1/20 | 0.44 |
| ▸ | NQO2 | P16083 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 2/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29415478 | 0.81 | CYP19A1 (0.60) | CYP19A1APPIKBKBCHUKIKBKG | |
| SCHEMBL403651 | 0.81 | CYP19A1 (0.60) | CYP19A1APPIKBKBCHUKIKBKG | |
| SCHEMBL29732980 | 0.80 | APP (0.63) | CYP19A1APPHSD17B1HSD17B2CA1 | |
| SCHEMBL845603 | 0.80 | APP (0.63) | CYP19A1APPHSD17B1HSD17B2CA1 | |
| SCHEMBL2517455 | 0.79 | CYP19A1 (0.59) | CYP19A1APPIKBKBCHUKIKBKG | |
| SCHEMBL6230863 | 0.79 | CYP19A1 (0.59) | CYP19A1APPIKBKBCHUKIKBKG | |
| SCHEMBL30109437 | 0.79 | CYP19A1 (0.59) | CYP19A1APPIKBKBCHUKIKBKG | |
| SCHEMBL30103498 | 0.79 | CYP19A1 (0.59) | CYP19A1APPIKBKBCHUKIKBKG | |
| SCHEMBL29675208 | 0.79 | CYP19A1 (0.59) | CYP19A1APPIKBKBCHUKIKBKG | |
| SCHEMBL27657937 | 0.79 | CYP19A1 (0.59) | CYP19A1APPIKBKBCHUKIKBKG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117256210-A | Composition for organic optoelectronic device, and display device | 三星SDI株式会社 | 2023-12-19 | — | — | CN | disclosed |
| EP-2563774-B1 | PYRIMIDINYL INDOLE COMPOUNDS | HUTCHISON MEDIPHARMA LTD (CN) | 2014-03-12 | — | — | EP | disclosed |
| US-8501166-B2 | Pyrimidinyl indole compounds | HUTCHISON MEDIPHARMA LIMITED (CN) | 2013-08-06 | — | — | US | disclosed |
| US-20130058892-A1 | PYRIMIDINYL INDOLE COMPOUNDS | HUTCHISON MEDIPHARMA LIMITED (CN) | 2013-03-07 | — | — | US | disclosed |
| EP-2563774-A1 | PYRIMIDINYL INDOLE COMPOUNDS | Hutchison Medipharma Limited (CN) | 2013-03-06 | — | — | EP | disclosed |
| WO-2011134140-A1 | PYRIMIDINYL INDOLE COMPOUNDS | HUTCHISON MEDIPHARMA LIMITED (CN) | 2011-11-03 | — | — | WO | disclosed |
| EP-1989200-B1 | [4-(BENZO[B]THIOPHEN-2-YL)-PYRIMIDIN-2-YL]-AMINE DERIVATIVES AS IKK-BETA INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | LILLY CO ELI (US) | 2009-07-29 | — | — | EP | disclosed |
| US-7547691-B2 | [4-(Benzo[B]thiophen-2-yl) Pyrimidin-2-yl]-amine derivatives as IKK-beta inhibitors for the treatment of cancer and inflammatory diseases | ELI LILLY AND COMPANY (US) | 2009-06-16 | — | — | US | disclosed |
| US-20080306082-A1 | [4-(Benzo[B]Thiophen-2-Yl) Pyrimidin-2-Yl]-Amine Derivatives As Ikk-Beta Inhibitors For The Treatment Of Cancer And Inflammatory Diseases | ELI LILLY AND COMPANY | 2008-12-11 | — | — | US | disclosed |
| EP-1989200-A2 | [4-(BENZO[B]THIOPHEN-2-YL)-PYRIMIDIN-2-YL]-AMINE DERIVATIVES AS IKK-BETA INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | ELI LILLY AND COMPANY (US) | 2008-11-12 | — | — | EP | disclosed |
| WO-2007092095-A2 | [4-(BENZO [B] THI0PHEN-2-YL) PYRIMIDIN-2YL] -AMINE DERIVATIVES AS IKK-BETA INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES. | ELI LILLY AND COMPANY (US) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306082-A1 | [4-(Benzo[B]Thiophen-2-Yl) Pyrimidin-2-Yl]-Amine Derivatives As Ikk-Beta Inhibitors For The Treatment Of Cancer And Inflammatory Diseases | NFKBIA, IKBKB, IKBKG | CYP19A1 1251/4885APP 645/4885HSD17B1 2078/4885 |
| US-20130058892-A1 | PYRIMIDINYL INDOLE COMPOUNDS | NFKBIA, JAK2, IRF3 | CYP19A1 2480/4885APP 2728/4885HSD17B1 3315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.